CROs begin consolidating site landscape
Major trends in drug development will reshape the global investigative site landscape. Trends to look out for include patient centricity and big data to CROs assuming responsibility for site effectiveness and patient recruitment. As the landscape evolves, sponsors and CROs will offer patients more convenient locations for clinical trial participation, motivated in large part by the desire to engage patients as partners in developing new medical treatments.
Realities of Precision Medicine
As biopharmaceutical companies increase R&D investment in precision medicine, a trend that is expected to rise by one-third in the next five years, clinical research professionals will need to implement operating practices and processes that can meet the complex demands of an individualized approach to drug development.
Precision medicine studies require the involvement of investigative sites that have experienced and highly trained staff able to handle complex, sophisticated protocols. Key challenges include the capability to collect and store frequent samples from patients, while also managing large amounts of data, including genomic information.
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.